UCLA announced that they have partnered with Roche to give UCLA stem cell and cancer scientists early access to leading-edge technologies in an effort to advance medical research. The agreement the researchers with leading-edge technologies, which will drive research capabilities and further the understanding of complex disease. The technologies, including the latest generation microarray systems from Roche NimbleGen, high-throughput screening instruments, genetic expression profilers and exome sequencing technologies will provide scientists with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and UCLA’s Jonsson Comprehensive Cancer Center with valuable technology directly from Roche’s research and development pipeline.